Menlo Park, California

Overall Rank: 297
Category: Biotech
Category Rank: 100


  • Top HealthTech Company of 2022


BillionToOne is a molecular diagnostics company with a mission to make molecular diagnostics more powerful, accurate, and accessible for all. BillionToOne’s proprietary Quantitative Counting Templates, or QCT(TM), platform unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. This technology quantifies molecules at the single base-pair level. Unity Screen(TM), BillionToOne’s commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow 300%+ year over year and may become the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. BillionToOne has also recently used its QCT technology to develop therapy selection and therapy monitoring products for cancer, Northstar Select (TM) and Northstar Response (TM), currently available for research use and expected to be available commercially early next year.

BilionToOne has raised more than $200 million in funding, with their most recent Series C funding round of $125 million closing in March 2022. The company’s prominent investors have previously invested in companies such as SpaceX, Uber, Spotify, Palantir, Braintree, WebMD, and DexCom. BillionToOne was founded in 2016 and is led by Co-Founder and CEO Oguzhan Atay, PhD.


Key Products

UNITY Screen™

UNITY Screen™ is the only commercially available non-invasive prenatal screen in the US that assesses fetal risk for aneuploidies and recessive conditions from a maternal blood draw at 10+ weeks into pregnancy. We are able to quantify the tiny DNA changes floating in cell-free DNA using our molecular counting technology.

The Northstar Select™

The Northstar Select™ provides a prioritized list of mutations that are present in the tumor. The types of mutations detected include deletions, insertions, and point-mutations. At the same time, it helps rule-in / rule-out relationship of mutations to drugs and provides an accurate read on the covered genes.

The Northstar Response™

The Northstar Response™ provides longitudinal determination of cancer burden via methylation assessment.